drugset / Trial / NCT04481243

A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes

NCT04481243

Phase 4 Completed 29 enrolled Mayo Clinic
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine if children with type 1 diabetes have adequate immune response to PPSV23 vaccination and to assess factors affecting immune response.

Timeline

Start
2021-04-30
Primary completion
2023-01-20
Completion
2023-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Pneumovax 23 Vaccine Intramuscular